<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test</h2>
    <div class="badge">2025-09-15T13:00:00+00:00</div>
    <ul>
      <li>PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorec</li>
<li>The Idylla™ CDx MSI Test aids in identifying eligible microsatellite instability-high (MSI-H) colorectal cancer (CRC) patients, who may benefit from treatment with OPDIVO® (nivolumab) alone, or in combination with YERVOY</li>
<li>The Test runs in a single-use cartridge, requiring less than three minutes of hands-on-time and delivering straightforward results in under three hours.</li>
<li>“Achieving FDA approval for our Idylla™ CDx MSI Test represents a key milestone for Biocartis,&quot; said Michael Korn, M.D., Chief Medical and Scientific Officer at Biocartis.</li>
<li>With its speed, accuracy, and automation, the Idylla™ CDx MSI Test offers a powerful solution that enables clinicians to make timely, confident and data-driven treatment decisions when every moment counts.”</li>
<li>“It underscores our commitment to helping oncology patients receive the right therapy without delay and the recent CheckMate-8HW data reinforce the critical importance of accurate MSI-H/dMMR testing in colorectal cancer.</li>
<li>“The approval of this new MSI companion diagnostic for patients with colorectal cancer is a meaningful achievement from our collaboration with Biocartis and a strong reflection of our Precision Medicine strategy at Brist</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Press%20Release%20Biocartis%20NV%3A%20Biocartis%20Receives%20FDA%20Approval%20for%20the%20Idylla%E2%84%A2%20CDx%20MSI%20Test%0A%E2%80%A2%20PRESS%20RELEASE%20-%2009%2F15%2F2025%2C%2009%3A00%20AM%20EDT%20Biocartis%20Receives%20FDA%20Approval%20for%20the%20Idylla%E2%84%A2%20CDx%20MSI%20Test%20First-ever%20fully%20automated%2C%20sample-to-result%2C%20cartridge-based%20companion%20diagnostic%20test%20approved%20in%20the%20US%20for%20colorec%0A%E2%80%A2%20The%20Idylla%E2%84%A2%20CDx%20MSI%20Test%20aids%20in%20identifying%20eligible%20microsatellite%20instability-high%20%28MSI-H%29%20colorectal%20cancer%20%28CRC%29%20patients%2C%20who%20may%20benefit%20from%20treatment%20with%20OPDIVO%C2%AE%20%28nivolumab%29%20alone%2C%20or%20in%20combination%20with%20YERVOY%0A%E2%80%A2%20The%20Test%20runs%20in%20a%20single-use%20cartridge%2C%20requiring%20less%20than%20three%20minutes%20of%20hands-on-time%20and%20delivering%20straightforward%20results%20in%20under%20three%20hours.%0A%E2%80%A2%20%E2%80%9CAchieving%20FDA%20approval%20for%20our%20Idylla%E2%84%A2%20CDx%20MSI%20Test%20represents%20a%20key%20milestone%20for%20Biocartis%2C%22%20said%20Michael%20Korn%2C%20M.D.%2C%20Chief%20Medical%20and%20Scientific%20Officer%20at%20Biocartis.%0A%E2%80%A2%20With%20its%20speed%2C%20accuracy%2C%20and%20automation%2C%20the%20Idylla%E2%84%A2%20CDx%20MSI%20Test%20offers%20a%20powerful%20solution%20that%20enables%20clinicians%20to%20make%20timely%2C%20confident%20and%20data-driven%20treatment%20decisions%20when%20every%20moment%20counts.%E2%80%9D%0A%E2%80%A2%20%E2%80%9CIt%20underscores%20our%20commitment%20to%20helping%20oncology%20patients%20receive%20the%20right%20therapy%20without%20delay%20and%20the%20recent%20CheckMate-8HW%20data%20reinforce%20the%20critical%20importance%20of%20accurate%20MSI-H%2FdMMR%20testing%20in%20colorectal%20cancer.%0A%E2%80%A2%20%E2%80%9CThe%20approval%20of%20this%20new%20MSI%20companion%20diagnostic%20for%20patients%20with%20colorectal%20cancer%20is%20a%20meaningful%20achievement%20from%20our%20collaboration%20with%20Biocartis%20and%20a%20strong%20reflection%20of%20our%20Precision%20Medicine%20strategy%20at%20Brist&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fpress-release-biocartis-nv-biocartis-receives-fda-approval-for-the-idylla-cdx-ms%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/press-release-biocartis-nv-biocartis-130000684.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>